公开(公告)号：US20140309289A1

公开(公告)日：2014-10-16

申请号：US14254771

申请日：2014-04-16

申请人： The Regents of the University of California

发明人： Joseph Anderson ,  Gerhard Bauer ,  Jan A. Nolta

IPC分类号： C12N15/86

CPC分类号： A61K48/0066 ,  A61K31/7105 ,  A61K38/53 ,  C07K14/7158 ,  C12N7/00 ,  C12N15/1138 ,  C12N15/86 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/531 ,  C12N2320/31 ,  C12N2320/32 ,  C12N2740/16011 ,  C12N2740/16043 ,  C12N2740/16051 ,  C12Y603/02

摘要： Recombinant lentiviral vectors containing at least: a lentiviral backbone comprising essential lentiviral sequences for integration into a target cell genome; a nucleic acid encoding a CCR5 RNAi; and an expression control element that regulates expression of the nucleic acid encoding the CCR5 RNAi element, are provided by this invention. In an alternative aspect, the vector also contains polynucleotides encoding TRIM5 alpha and HIV TAR decoy sequences along with gene expression regulation elements such as promoters operatively linked to the polynucleotides. The vectors are combined with packaging plasmid and envelope plasmids and optionally conjugated to cell-specific targeting antibodies. Diagnostic and therapeutic methods for using the compositions are further provided herein.

摘要翻译： 含有至少包含慢病毒骨架的重组慢病毒载体，其包含用于整合入靶细胞基因组的必需慢病毒序列; 编码CCR5 RNAi的核酸; 和调节编码CCR5 RNAi元件的核酸表达的表达控制元件由本发明提供。 在另一方面，载体还含有编码TRIM5α和HIV TAR诱饵序列的多核苷酸以及基因表达调控元件，例如与多核苷酸可操作连接的启动子。 将载体与包装质粒和包膜质粒组合，并任选地与细胞特异性靶向抗体缀合。 本文进一步提供了使用组合物的诊断和治疗方法。

公开(公告)号：US20040152871A1

公开(公告)日：2004-08-05

申请号：US10275602

申请日：2004-03-23

发明人： Toshihiro Nakajima ,  Tetsuya Amano

IPC分类号： C07K014/47 ,  C07H021/04

CPC分类号： C12N15/8509 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0325 ,  A61K38/00 ,  C12N9/104 ,  C12N9/93 ,  C12Y203/02 ,  C12Y603/02 ,  G01N33/564 ,  G01N33/574 ,  G01N2500/00

摘要： The present invention discloses a novel protein called Synoviolin and a gene that encodes it. This protein is expressed specifically by synovial tissue and also accompanies the presence of an auto-antibody that recognizes this protein in rheumatoid arthritis (RA) patients. The protein according to the present invention and its antibody can be expected to be used as specific diagnostic markers for RA. In addition, the gene or protein according to the present invention may be used to permit the screening of drugs to treat RA. Moreover, the present invention provides synoviolin gene transgenic animals. The transgenic animals according to the present invention can be used as RA model animals in the development of pharmaceuticals to treat RA.

摘要翻译： 本发明公开了一种称为Synoviolin的新型蛋白质及其编码基因。 该蛋白质通过滑膜组织特异性表达，并且还伴随着在类风湿性关节炎（RA）患者中识别该蛋白质的自身抗体的存在。 根据本发明的蛋白质及其抗体可以预期用作RA的特异性诊断标记物。 此外，根据本发明的基因或蛋白质可用于允许筛选药物以治疗RA。 此外，本发明提供滑膜素基因转基因动物。 根据本发明的转基因动物可用作RA模型动物，用于开发药物以治疗RA。

公开(公告)号：US20180161298A1

公开(公告)日：2018-06-14

申请号：US15813438

申请日：2017-11-15

申请人： STC.UNM

发明人： Vojo P. Deretic ,  Michael Mandell

IPC分类号： A61K31/201 ,  C12N9/00 ,  A61K38/53 ,  C12Q1/44 ,  C12Q1/61 ,  A61K45/06

CPC分类号： A61K31/201 ,  A61K38/53 ,  A61K45/06 ,  C12N9/93 ,  C12Q1/44 ,  C12Q1/61 ,  C12Y603/02 ,  G01N2333/92 ,  G01N2405/00 ,  G01N2405/02 ,  G01N2500/20 ,  G01N2800/7028

摘要： The present invention relates to the use of neutral lipids, including triglycerides, diglycerides and monoglycerides which may be used to increase neutral lipids (lipid stores and/or lipid droplets) and neutral lipid stores in order to regulate (in particular, induce) autophagy and treat and/or prevent autophagy related disease states and/or conditions. In one embodiment, the invention relates to the use of neutral lipids and/or TRIM proteins which may be used to regulate (in particular, induce) autophagy, target autophagic substrates and treat and/or prevent autophagic disease states and/or conditions.

公开(公告)号：US09970036B2

公开(公告)日：2018-05-15

申请号：US14776805

申请日：2014-03-14

申请人： Modular Genetics, Inc.

发明人： Kevin A. Jarrell ,  Gabriel O. Reznik ,  Prashanth Vishwanath ,  Michelle Pynn

IPC分类号： C12N1/20 ,  C12P13/02 ,  C12N9/00 ,  A01N37/36 ,  C07C235/06

CPC分类号： C12P13/02 ,  A01N37/36 ,  C07C235/06 ,  C12N9/93 ,  C12Y603/02

摘要： Engineered polypeptides useful in synthesizing acyl amino acids are provided. Also provided are methods of making acyl amino acids using engineered polypeptides.

公开(公告)号：US20170362593A1

公开(公告)日：2017-12-21

申请号：US15536437

申请日：2015-12-21

申请人： Centre National De La Recherche Scientifique

发明人： Domenico Maiorano

IPC分类号： C12N15/113 ,  A61K31/381 ,  G01N33/574 ,  A61K31/713 ,  C12Q1/68

CPC分类号： C12N15/1137 ,  A61K31/255 ,  A61K31/381 ,  A61K31/4745 ,  A61K31/555 ,  A61K31/7105 ,  A61K31/713 ,  A61K33/24 ,  C07K16/18 ,  C07K16/40 ,  C12N9/93 ,  C12N15/113 ,  C12N2310/14 ,  C12N2320/31 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y203/02 ,  C12Y603/02 ,  G01N33/57496 ,  G01N2333/9108 ,  G01N2800/52

摘要： The present invention relates to the use of an inhibitor of Rad18 expression or activity, in treating a tumor or in sensitizing a patient affected with a tumor, to a treatment with an antineoplastic agent that is a DNA damaging chemotherapeutic agent so to both reduce the self renewal of cancer stem cells and increase the DNA damage response thus boosting apoptotic cell death.

公开(公告)号：US09840708B2

公开(公告)日：2017-12-12

申请号：US14350166

申请日：2012-10-05

申请人： Dana-Farber Cancer Institute, Inc.

发明人： Margaret A. Shipp ,  Qingsheng Yan

IPC分类号： C12N15/113 ,  C12N15/85 ,  C12Q1/68 ,  G01N33/574 ,  C07K16/40 ,  C12N9/10 ,  C12N9/00 ,  C12Q1/25 ,  C12Q1/48 ,  G01N33/573

CPC分类号： C12N15/1137 ,  C07K16/40 ,  C12N9/1077 ,  C12N9/93 ,  C12N15/8509 ,  C12N2015/859 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/16 ,  C12N2320/30 ,  C12N2320/31 ,  C12Q1/25 ,  C12Q1/48 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Y204/0203 ,  C12Y603/02 ,  C12Y603/02019 ,  G01N33/573 ,  G01N33/57484 ,  G01N2333/9015 ,  G01N2333/91142 ,  G01N2500/10 ,  G01N2800/52

摘要： The invention provides methods and compositions for enhancing the efficacy of cancer therapies through modulation of BAL1 and/or BBAP. Also provided are methods for predicting the efficacy of cancer therapies or treating cancer in a subject through modulation of BAL1 and/or BBAP. Further provided are methods for identifying compounds that are capable of modulating BAL1-BBAP complexes.

公开(公告)号：US20170157145A1

公开(公告)日：2017-06-08

申请号：US15332306

申请日：2016-10-24

申请人： Samsung Electronics Co., Ltd. ,  Research & Business Foundation, Sungkyunkwan University

发明人： Yunil Lee ,  Yunjong Lee ,  Sangwoo Ham ,  Sangchul Park ,  Jooho Shin

IPC分类号： A61K31/573 ,  G01N33/50 ,  C12N9/00 ,  A61K31/4196 ,  A61K31/407

CPC分类号： A61K31/573 ,  A61K31/407 ,  A61K31/4196 ,  C12N9/93 ,  C12Y603/02 ,  G01N33/5023 ,  G01N33/5058 ,  G01N33/6896 ,  G01N2333/9015 ,  G01N2800/2814 ,  G01N2800/2835

摘要： A method of inducing Parkin expression; inhibiting oxidative stress; and inhibiting cell death of cells by administering deferasirox, hydrocortisone, ketorolac, dexamethasone, and prednisone, a pharmaceutically acceptable salt, stereoisomer, derivative, or solvate thereof to the cell, optionally in a subject, as well as a method of preventing or treating neurodegenerative disease in the subject.

公开(公告)号：US20160319253A1

公开(公告)日：2016-11-03

申请号：US15105141

申请日：2014-12-18

申请人： NATIONAL CANCER CENTER ,  LSIP, LLC

发明人： Tatsuhiro SHIBATA ,  Fumie HOSODA

IPC分类号： C12N9/12 ,  C07K14/475 ,  C12N9/00 ,  C07K14/705 ,  C12Q1/68 ,  C12N15/113

CPC分类号： C12N9/12 ,  C07K14/47 ,  C07K14/4747 ,  C07K14/4756 ,  C07K14/705 ,  C07K14/715 ,  C07K2319/00 ,  C12N9/93 ,  C12N15/113 ,  C12N15/1137 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Y207/10001 ,  C12Y207/11001 ,  C12Y603/02 ,  G01N33/57446

摘要： To identify mutations that can serve as indicators for predicting the effectiveness of drug treatments in cancers such as gastric cancer; to provide a means for detecting said mutations; and to provide a means for identifying, based on said mutations, patients with cancer or subjects with a risk of cancer, in whom drugs targeting genes having said mutations or proteins encoded by said genes show a therapeutic effect.A method for detecting a gene fusion serving as a responsible mutation (driver mutation) for cancer, the method comprising the step of detecting any one of an ATG3-EPHB1 fusion polynucleotide, a TNIK-RNF123 fusion polynucleotide, or an SLC12A2-NRG2 fusion polynucleotide, or a polypeptide encoded thereby, in an isolated sample from a subject.

摘要翻译： 一种用于检测用于癌症的负责突变（驱动突变）的基因融合的方法，所述方法包括检测ATG3-EPHB1融合多核苷酸，TNIK-RNF123融合多核苷酸或SLC12A2-NRG2融合多核苷酸中的任一种的步骤 ，或由其编码的多肽，来自受试者的分离的样品中。

公开(公告)号：US09309535B2

公开(公告)日：2016-04-12

申请号：US14254771

申请日：2014-04-16

申请人： The Regents of the University of California

发明人： Joseph Anderson ,  Gerhard Bauer

IPC分类号： C07H21/04 ,  C12N15/86 ,  C07K14/715 ,  C12N15/113

CPC分类号： A61K48/0066 ,  A61K31/7105 ,  A61K38/53 ,  C07K14/7158 ,  C12N7/00 ,  C12N15/1138 ,  C12N15/86 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/531 ,  C12N2320/31 ,  C12N2320/32 ,  C12N2740/16011 ,  C12N2740/16043 ,  C12N2740/16051 ,  C12Y603/02

摘要： Recombinant lentiviral vectors containing at least: a lentiviral backbone comprising essential lentiviral sequences for integration into a target cell genome; a nucleic acid encoding a CCR5 RNAi; and an expression control element that regulates expression of the nucleic acid encoding the CCR5 RNAi element, are provided by this invention. In an alternative aspect, the vector also contains polynucleotides encoding TRIM5 alpha and HIV TAR decoy sequences along with gene expression regulation elements such as promoters operatively linked to the polynucleotides. The vectors are combined with packaging plasmid and envelope plasmids and optionally conjugated to cell-specific targeting antibodies. Diagnostic and therapeutic methods for using the compositions are further provided herein.

摘要翻译： 含有至少包含慢病毒骨架的重组慢病毒载体，其包含用于整合入靶细胞基因组的必需慢病毒序列; 编码CCR5 RNAi的核酸; 和调节编码CCR5 RNAi元件的核酸表达的表达控制元件由本发明提供。 在另一方面，载体还含有编码TRIM5α和HIV TAR诱饵序列的多核苷酸以及基因表达调控元件，例如与多核苷酸可操作连接的启动子。 将载体与包装质粒和包膜质粒组合，并任选地与细胞特异性靶向抗体缀合。 本文进一步提供了使用组合物的诊断和治疗方法。

公开(公告)号：US09186373B2

公开(公告)日：2015-11-17

申请号：US13977453

申请日：2011-12-27

申请人： Günther Lametschwandtner ,  Hans Loibner ,  Manfred Schuster ,  Isabella Haslinger ,  Sandra Seidl

发明人： Günther Lametschwandtner ,  Hans Loibner ,  Manfred Schuster ,  Isabella Haslinger ,  Sandra Seidl

IPC分类号： C07H21/04 ,  A61K31/713 ,  A61K38/20 ,  C12N15/113 ,  A61K38/21

CPC分类号： A61K31/713 ,  A61K9/127 ,  A61K38/20 ,  A61K38/2013 ,  A61K38/208 ,  A61K38/212 ,  A61K38/215 ,  C12N15/1137 ,  C12N2310/14 ,  C12Y603/02 ,  A61K2300/00

摘要： The invention relates to a method for the immune activation of NK cells by the reduction or inhibition of the Cbl-b function in said cells. This stimulates the congenital immune system and thus permits the therapy of appropriate diseases.

摘要翻译： 本发明涉及通过减少或抑制所述细胞中Cbl-b功能来免疫激活NK细胞的方法。 这刺激了先天性免疫系统，从而允许治疗适当的疾病。